Mangoceuticals, Inc.
MGRX
$0.37
$0.038.45%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 414.60K | 456.00K | 466.80K | 516.00K | 511.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 414.60K | 456.00K | 466.80K | 516.00K | 511.10K |
| Cost of Revenue | 197.30K | 205.60K | 183.80K | 201.20K | 216.40K |
| Gross Profit | 217.30K | 250.40K | 283.00K | 314.80K | 294.70K |
| SG&A Expenses | 16.37M | 16.44M | 17.77M | 11.80M | 8.75M |
| Depreciation & Amortization | 1.12M | 1.12M | 721.50K | 721.50K | 721.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.69M | 17.77M | 18.68M | 12.72M | 9.68M |
| Operating Income | -17.27M | -17.32M | -18.21M | -12.21M | -9.17M |
| Income Before Tax | -19.21M | -20.64M | -19.82M | -14.20M | -11.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.21 | -20.64 | -19.82 | -14.20 | -11.18 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 400.00 | 500.00 | 900.00 | 800.00 | 1.10K |
| Net Income | -19.21M | -20.64M | -19.82M | -14.20M | -11.18M |
| EBIT | -17.27M | -17.32M | -18.21M | -12.21M | -9.17M |
| EBITDA | -15.67M | -15.59M | -16.22M | -10.23M | -8.00M |
| EPS Basic | -1.67 | -2.56 | -3.09 | -3.54 | -4.37 |
| Normalized Basic EPS | -0.94 | -1.47 | -1.87 | -2.07 | -2.60 |
| EPS Diluted | -1.67 | -2.56 | -3.09 | -3.54 | -4.37 |
| Normalized Diluted EPS | -0.94 | -1.47 | -1.87 | -2.07 | -2.60 |
| Average Basic Shares Outstanding | 52.18M | 40.29M | 28.72M | 19.21M | 10.97M |
| Average Diluted Shares Outstanding | 52.18M | 40.29M | 28.72M | 19.21M | 10.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |